Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Tempus

Tempus AI: Volatility Equates to Opportunity in AI Leader

Tempus AI is well-positioned to accelerate growth as its investments in healthcare-focused AI pay off. Analysts are raising their targets.

MarketBeat

Tempus AI Q3 Highlights: Cathie Wood-, Nancy Pelosi-Owned AI Stock Raises Guidance

AI company Tempus AI (NASDAQ:TEM) reported third-quarter financial results Tuesday after market close.

Benzinga

Ark Invest Dumps AMD Stock, Doubles Down On Chinese Tech Giants Alibaba And Baidu

On Thursday, Cathie Wood‘s Ark Invest made significant trades involving Alibaba Group Holding Ltd (NYSE:BABA), Baidu Inc (NASDAQ:BIDU), Advanced Micro Devices Inc (NASDAQ:AMD), and Tempus AI Inc (NASDAQ:TEM). These trades reflect Ark’s strategic positioning in the tech sector, with purchases and sales across multiple funds.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Tempus AI Shares Are Trading Higher Monday: What's Going On?

Tempus AI (NASDAQ:TEM) shares are trading higher Monday after the company announced its subsidiary, Ambry Genetics, published a peer reviewed study in Genetics in Medicine.

Benzinga

IonQ, Tempus AI And AeroVironment Are Among Top 10 Large Cap Losers Last Week (Oct. 13-Oct. 17): Are the Others in Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Benzinga

Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership

Whitehawk Therapeutics Inc. (NASDAQ:WHWK) dropped 8.81% in after-hours trading Thursday, closing at $2.38, after announcing a multi-year collaboration with Tempus AI.

Benzinga

Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc (NASDAQ:TEM) to support the development of its oncology pipeline.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Tempus AI Hits $100—Are Shares Due for a Pullback?

After hitting $100, Tempus AI has retreated, but shares have still provided huge returns. Multiple factors suggest that the stock could see a larger correction.

MarketBeat

Tempus AI Up Nearly 185% Since Nancy Pelosi's Reported Purchase In January 2025

Investors who followed the stock market disclosures from former House Speaker Nancy Pelosi would have seen significant returns, as an investment in the artificial intelligence health company Tempus AI Inc. (NASDAQ:TEM) has surged in value.

Benzinga

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall

Tempus AI Inc (NASDAQ:TEM) has become one of 2025's most dramatic comeback stories. The stock soared past $100 this week, marking a new 52-week high and sending the market buzzing about the AI-powered cancer diagnostics company's growth prospects. Investors are taking note as the stock climbs amid recent FDA clearances…

Benzinga

Tempus AI (TEM) Stock Is Rising Wednesday: What's Going On?

Shares of Tempus AI Inc (NASDAQ:TEM) are trading higher Wednesday, potentially building on momentum from last week given the lack of company-specific news. Here’s what investors need to know.

Benzinga

3 Healthcare Stocks Using AI to Drive Growth

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

MarketBeat

Tempus AI (TEM) Stock Is Rising Monday: What's Going On?

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Monday morning after the company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.

Benzinga

This AI Stock Has More Than Doubled in 2025. Is It a Buy?

After a remarkable triple-digit surge so far in 2025, is now the time to buy the shares of this AI stock?

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What's Going On With Tempus AI Stock Monday?

Tempus AI Inc (NASDAQ:TEM) stock is trading marginally lower on Monday, showing little movement after a 7% gain last week. On Friday, HC Wainwright Co. analyst Yi Chen reiterated a Buy rating on the artificial intelligence and precision medicine company, raising the price target to $98 from $90.

Benzinga

Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging

On Thursday, Tempus AI, Inc. (NASDAQ:TEM) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform.

MarketBeat

3 Heavily Shorted Stocks That Could Prove the Bears Wrong

Bearish investors are hammering these three stocks with short selling. However, all three have promising developments on their side that bears may be missing.

Cycling Weekly

Are these the wheels to help me break the 19-minute 10-mile time trial barrier? I reviewed the Scribe Tempus Disc/100 wheels to find out

The Scribe Tempus Disc/100 wheelset is a quality, lightweight time trial solution designed to bring top-tier performance to the people

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Tempus AI Expands Into Digital Pathology With Paige Acquisition

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital pathology.

MarketBeat

Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?

Tempus AI fired on all cylinders in Q2, and Morgan Stanley upgraded the stock. What is the near and long-term outlook for this name, up 89% in 2025?

Benzinga

Under the Radar: Four Emerging Picks From a Century-Old Growth Investing Powerhouse

Most of those reading this have never heard of Baillie Gifford. The UK investment firm is not really a household name here in the United States.

Benzinga

Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday.

Benzinga

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Imagine you stepped into the dimly lit hospital meeting room to pitch a new cancer‑diagnostic deal. You flick through slides powered by Palantir Technologies Inc.'s (NASDAQ:PLTR) Foundry platform, showcasing data transparency and precision that would make legacy pharma pipelines look prehistoric.

Benzinga

Tempus AI Stock Is Rising Wednesday: What's Happening?

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software.

Benzinga

Cathie Wood Bets Another $1 Million On Tempus AI Despite Jim Cramer's Doubts, Dumps Crypto Stocks As Bitcoin Hits Fresh New Highs

On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. (NASDAQ:TEM), Coinbase Global Inc. (NASDAQ:COIN), Robinhood Markets Inc. (NASDAQ:HOOD), and Block Inc. (NYSE:XYZ).

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.